AstraZeneca Expands Use of Innaphase Watson™ Laboratory Information Management System in the United Kingdom
AstraZeneca Expands Use of Innaphase Watson™ Laboratory Information Management System in the United Kingdom
PHILADELPHIA, (June 4, 2003) — InnaPhase Corporation, a leading provider of LIMS solutions for the life sciences, today announced that AstraZeneca has implemented the WatsonTM Laboratory Information Management System (LIMS) in their Adlerley Park Research and Development Center based in the United Kingdom. AstraZeneca is also using the Watson LIMS product within their facilities in Charnwood, United Kingdom, Lund, Sweden and Wilmington, Delaware in the United States.
Watson LIMS, a solution within the Pharma LIMS™ Suite, is specifically designed to support DMPK/Bioanalytical studies in drug development while ensuring regulatory compliance with the FDA’s 21 CFR Part 11 guidance on electronic records and signatures. Watson has an established track record of accelerating bioanalysis, sample management and regulatory compliance in pharmaceutical drug development.
“AstraZeneca has one of the best new product pipelines in the industry,” said Dave Sweetmore, Business Project Manager. “By using innovative technology such as Watson LIMS, we will enable our scientists to make more rapid and informed decisions in order to continue to produce the highest quality of results possible.”
“We are pleased that AstraZeneca has chosen to expand their use of Watson,” said Jo Webber, Ph.D, President and CEO of InnaPhase Corporation. “I am certain that Watson will provide AstraZeneca with significant cost savings and a quick return on their investment.”
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.
InnaPhase Corporation provides 18 of the world’s top 20 pharmaceutical organizations with its products and services. The Pharma LIMS ™ Suite is a series of purpose built LIMS applications for the pharmaceutical industry and is designed to operate in a 21 CFR Part 11 compliant environment. The Pharma LIMS Suite includes: Newton™ LIMS for batch release, quality control, formulation, stability and analytical development; Watson™ LIMS for pre-clinical and clinical bioanalysis; and Galileo™ LIMS for In Vitro testing. InnaPhase has locations in the United States and the United Kingdom as well as distribution and support centers in India and Japan. For more information, see InnaPhase on the World Wide Web at www.innaphase.com
NOTE TO EDITORS:
For a complete media information kit on InnaPhase Products and Services, contact Karen Horan at InnaPhase Corporation, 215-964-6055 or e-mail khoran@innaphase.com.
